AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
Director Dennis M. Fenton of AnaptysBio reported a significant insider transaction on June 18, 2025. The filing details:
- Sale of 3,015 shares of Common Stock at $23.97 per share
- Transaction was executed under a Rule 10b5-1 trading plan established on March 22, 2024
- The sale was primarily to satisfy tax obligations related to restricted stock unit vesting on June 15, 2025
- Following the transaction, Fenton retains direct ownership of 4,965 shares
This transaction appears to be a planned sale for tax purposes rather than a discretionary trade, as evidenced by the pre-established 10b5-1 plan. The sale represents a partial liquidation of Fenton's holdings, maintaining a significant ownership position in the company.
Director Hollings Renton of AnaptysBio reported a sale of 3,015 shares of common stock at $23.97 per share on June 18, 2025. Following the transaction, Renton retains direct ownership of 4,965 shares.
Key details of the transaction:
- The sale was executed under a Rule 10b5-1 trading plan established on March 14, 2024
- The shares were sold to cover tax obligations related to the vesting of restricted stock units on June 15, 2025
- Total transaction value: approximately $72,269
This insider transaction represents a routine sale for tax purposes rather than a discretionary trading decision, as it was pre-planned through a 10b5-1 trading plan and specifically tied to RSU vesting obligations.
AnaptysBio (NASDAQ:ANAB) filed a routine Form 144 on June 29, 2025, notifying the SEC of a proposed sale of 3,015 common shares valued at approximately $72,269.55 (about $23.96 per share). The shares were originally received as restricted stock on June 15, 2025 and are expected to be sold around June 18, 2025 through Morgan Stanley Smith Barney. The filer reported no other sales in the past three months and affirmed that no undisclosed material adverse information is known. With 29,380,496 shares outstanding, the proposed sale represents a negligible fraction of total equity and does not indicate any material change to AnaptysBio’s operations or financial condition.